Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression-Reference-Cited by-同舟云学术

Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression

Published:2017-11 Issue:5 Volume:72 Page:835-844
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Wang Ronghao,Sun Yin,Li Lei,Niu Yuanjie,Lin Wanying,Lin Changyi,Antonarakis Emmanuel S.,Luo Jun,Yeh Shuyuan,Chang Chawnshang

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant;Sun;J Clin Invest,2010

2. Androgen receptor in prostate cancer;Heinlein;Endocr Rev,2004

3. Enzalutamide—a major advance in the treatment of metastatic prostate cancer;Vogelzang;N Engl J Med,2012

4. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer;Antonarakis;N Engl J Med,2014

5. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs;Yang;Nature,2013

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The m6A regulators in prostate cancer: molecular basis and clinical perspective;Frontiers in Pharmacology;2024-08-29

2. Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy;Frontiers in Pharmacology;2024-07-25

3. Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer;Cellular Signalling;2024-05

4. M2 Tumor‐Associated Macrophages‐Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression;Advanced Science;2024-04-19

5. Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells;Frontiers in Chemistry;2024-03-04